News
Asianet Newsable on MSN3h
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 UpsideThe data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in ...
A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...
NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...
Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...
Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...
Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...
USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback